Spots Global Cancer Trial Database for palbociclib 125mg
Every month we try and update this database with for palbociclib 125mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | NCT03936270 | Ovarian Cancer | Palbociclib 125... Letrozole 2.5mg | 18 Years - | Latin American Cooperative Oncology Group | |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | NCT05216432 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... | RLY-2608 Fulvestrant Palbociclib 125... Ribociclib 400m... Ribociclib 600m... | 18 Years - | Relay Therapeutics, Inc. | |
| Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer | NCT02630693 | Breast Cancer | Palbociclib 100... Palbociclib 125... Fulvestrant or ... | 18 Years - | Canadian Cancer Trials Group | |
| Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant | NCT03447132 | Breast Neoplasm... | Fulvestrant 500... Palbociclib 125... Goserelin 3.6 M... Placebos | 18 Years - | International Cancer Research Group, United Arab Emirates | |
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT03709082 | HER2-positive B... Breast Cancer M... | Palbociclib 75m... Letrozole 2.5mg T-DM1 Palbociclib 100... Palbociclib 125... Palbociclib | 18 Years - | University of Kansas Medical Center | |
| Combined Immunotherapies in Metastatic ER+ Breast Cancer | NCT04563507 | Breast Cancer | Stereotactic Bo... Letrozole 2.5Mg... Palbociclib 125... | 18 Years - 90 Years | Weill Medical College of Cornell University | |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | NCT03936270 | Ovarian Cancer | Palbociclib 125... Letrozole 2.5mg | 18 Years - | Latin American Cooperative Oncology Group | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | NCT01209598 | Sarcoma Liposarcoma | Palbociclib 200... Palbociclib 125... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer | NCT03123744 | Cancer, Advance... | Palbociclib 125... | 18 Years - | University of California, San Diego | |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer | NCT03123744 | Cancer, Advance... | Palbociclib 125... | 18 Years - | University of California, San Diego | |
| PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | NCT01209598 | Sarcoma Liposarcoma | Palbociclib 200... Palbociclib 125... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection | NCT03079011 | Metastatic Brea... | Palbociclib 125... Aromatase Inhib... Fulvestrant Inj... | 18 Years - | UNICANCER |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
